Literature DB >> 23160340

CYP3A4 overexpression enhances the cytotoxicity of the antitumor triazoloacridinone derivative C-1305 in CHO cells.

Ewa Augustin1, Barbara Borowa-Mazgaj, Agnieszka Kikulska, Milena Kordalewska, Monika Pawłowska.   

Abstract

AIM: To examine how the higher expression level of CYP3A4 isoenzyme influenced the cytotoxicity of the antitumor triazoloacridinone derivative C-1305 in Chinese hamster ovary (CHO) cells.
METHODS: Three CHO cell lines were examined: wild-type CHO cells; CHO-HR cells with overexpression of human cytochrome P450 reductase (CPR); and CHO-HR-3A4 cells with coexpression of human CYP3A4 and CPR. Cellular responses caused by C-1305 were monitored using DAPI staining, cell cycle analysis, phosphatydilserine externalization analysis and SA-β-galactosidase expression analysis. Cell viability was assessed with simultaneous FDA and PI staining.
RESULTS: Treatment with C-1305 for 72 h exhibited different levels of cytotoxicity in the 3 cell lines, and the values of IC80 in CHO, CHO-HR and CHO-HR-3A4 cells were 0.087±0.005, 0.032±0.0001, and 0.064±0.0095 μmol/L, respectively. The cell cycle analysis revealed that both CHO and CHO-HR cells underwent transient G(2)/M arrest, whereas CHO-HR-3A4 cells did not accumulate in this phase. Prolonged exposure up to 120 h caused time-dependent increase in the sub-G(1) fraction in all the 3 cell lines. Treatment with C-1305 caused cell death through apoptosis and necrosis. However, these processes were more pronounced in the transfected CHO cells than in the wild-type cells. The cells surviving after C-1305 exposure underwent senescence.
CONCLUSION: CYP3A4 overexpression potently enhances the cellular responses (apoptosis, necrosis and senescence) caused by C-1305 in CHO cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23160340      PMCID: PMC4086498          DOI: 10.1038/aps.2012.132

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  38 in total

1.  The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.

Authors:  Matthew P Goetz; Stacey K Knox; Vera J Suman; James M Rae; Stephanie L Safgren; Matthew M Ames; Daniel W Visscher; Carol Reynolds; Fergus J Couch; Wilma L Lingle; Richard M Weinshilboum; Emily G Barr Fritcher; Andrea M Nibbe; Zeruesenay Desta; Anne Nguyen; David A Flockhart; Edith A Perez; James N Ingle
Journal:  Breast Cancer Res Treat       Date:  2006-11-18       Impact factor: 4.872

2.  Induction of G2/M phase arrest and apoptosis of human leukemia cells by potent antitumor triazoloacridinone C-1305.

Authors:  Ewa Augustin; Anna Moś-Rompa; Anna Skwarska; Jacek M Witkowski; Jerzy Konopa
Journal:  Biochem Pharmacol       Date:  2006-09-12       Impact factor: 5.858

3.  A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents.

Authors:  B D Chang; E V Broude; M Dokmanovic; H Zhu; A Ruth; Y Xuan; E S Kandel; E Lausch; K Christov; I B Roninson
Journal:  Cancer Res       Date:  1999-08-01       Impact factor: 12.701

4.  Tumor-specific expression of cytochrome P450 CYP1B1.

Authors:  G I Murray; M C Taylor; M C McFadyen; J A McKay; W F Greenlee; M D Burke; W T Melvin
Journal:  Cancer Res       Date:  1997-07-15       Impact factor: 12.701

Review 5.  Cytochrome P-450 3A4: regulation and role in drug metabolism.

Authors:  F P Guengerich
Journal:  Annu Rev Pharmacol Toxicol       Date:  1999       Impact factor: 13.820

6.  Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene.

Authors:  L Chen; L J Yu; D J Waxman
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

7.  Antitumor activity of methoxymorpholinyl doxorubicin: potentiation by cytochrome P450 3A metabolism.

Authors:  Hong Lu; David J Waxman
Journal:  Mol Pharmacol       Date:  2004-10-01       Impact factor: 4.436

8.  Interactions of antitumor triazoloacridinones with DNA.

Authors:  Marcin Koba; Jerzy Konopa
Journal:  Acta Biochim Pol       Date:  2007-04-19       Impact factor: 2.149

9.  Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas.

Authors:  Cristina Rodríguez-Antona; Susanna Leskelä; Magdalena Zajac; Marta Cuadros; Javier Alvés; Maria Victoria Moneo; Carmen Martín; Juan Cruz Cigudosa; Amancio Carnero; Mercedes Robledo; Javier Benitez; Beatriz Martínez-Delgado
Journal:  Blood       Date:  2007-07-18       Impact factor: 22.113

10.  Induction of unique structural changes in guanine-rich DNA regions by the triazoloacridone C-1305, a topoisomerase II inhibitor with antitumor activities.

Authors:  Krzysztof Lemke; Marcin Wojciechowski; William Laine; Christian Bailly; Pierre Colson; Maciej Baginski; Annette K Larsen; Andrzej Skladanowski
Journal:  Nucleic Acids Res       Date:  2005-10-27       Impact factor: 16.971

View more
  3 in total

1.  CYP3A4 overexpression enhances apoptosis induced by anticancer agent imidazoacridinone C-1311, but does not change the metabolism of C-1311 in CHO cells.

Authors:  Monika Pawłowska; Ewa Augustin; Zofia Mazerska
Journal:  Acta Pharmacol Sin       Date:  2013-12-02       Impact factor: 6.150

Review 2.  Mechanisms of Taxane Resistance.

Authors:  Sara M Maloney; Camden A Hoover; Lorena V Morejon-Lasso; Jenifer R Prosperi
Journal:  Cancers (Basel)       Date:  2020-11-10       Impact factor: 6.639

3.  Enhanced Activity of P4503A4 and UGT1A10 Induced by Acridinone Derivatives C-1305 and C-1311 in MCF-7 and HCT116 Cancer Cells: Consequences for the Drugs' Cytotoxicity, Metabolism and Cellular Response.

Authors:  Monika Pawłowska; Anna Kwaśniewska; Zofia Mazerska; Ewa Augustin
Journal:  Int J Mol Sci       Date:  2020-05-31       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.